儿科肿瘤学
Pediatric oncology.
作者信息
Davidoff Andrew M
机构信息
Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-3678, USA.
出版信息
Semin Pediatr Surg. 2010 Aug;19(3):225-33. doi: 10.1053/j.sempedsurg.2010.03.007.
Abstract
Cancer is a disease whose progression is driven by a series of accumulating genetic and epigenetic changes influenced by hereditary factors and the somatic environment. These changes result in individual cells acquiring a phenotype that provides those cells with a survival advantage over surrounding normal cells. Our understanding of the processes that occur in malignant transformation is increasing, with many discoveries in cancer cell biology having been made through the study of childhood tumors. The processes involved in oncogenesis and cancer progression will be discussed in this review.
摘要
癌症是一种疾病，其进展由一系列累积的遗传和表观遗传变化驱动，这些变化受遗传因素和体细胞环境影响。这些变化导致单个细胞获得一种表型，使这些细胞比周围的正常细胞具有生存优势。我们对恶性转化过程的理解正在不断加深，通过对儿童肿瘤的研究，在癌细胞生物学方面有了许多发现。本综述将讨论肿瘤发生和癌症进展所涉及的过程。
相似文献
1
Pediatric oncology.
Semin Pediatr Surg. 2010 Aug;19(3):225-33. doi: 10.1053/j.sempedsurg.2010.03.007.
2
Cancer: an epigenetic landscape.
Subcell Biochem. 2013;61:399-417. doi: 10.1007/978-94-007-4525-4_17.
3
Introduction: Cancer biomarkers and fertility.
Fertil Steril. 2018 Jan;109(1):4-5. doi: 10.1016/j.fertnstert.2017.12.009.
4
Epigenetic changes during cell transformation.
Adv Exp Med Biol. 2013;754:179-94. doi: 10.1007/978-1-4419-9967-2_9.
5
Epigenetic regulation of cancer stem cell gene expression.
Subcell Biochem. 2013;61:419-34. doi: 10.1007/978-94-007-4525-4_18.
6
Epigenetic changes in cancer.
Annu Rev Pathol. 2009;4:229-49. doi: 10.1146/annurev.pathol.3.121806.151442.
7
Genetic Counselor Recommendations for Cancer Predisposition Evaluation and Surveillance in the Pediatric Oncology Patient.
Clin Cancer Res. 2017 Jul 1;23(13):e91-e97. doi: 10.1158/1078-0432.CCR-17-0834.
8
Genetic Predisposition to Neonatal Tumors.
Curr Pediatr Rev. 2015;11(3):164-78. doi: 10.2174/1573396311666150714110229.
9
Genetics of cancer predisposition and progression.
Clin Investig. 1993 Jun;71(6):488-502. doi: 10.1007/BF00180066.
10
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
Lancet Oncol. 2018 Jun;19(6):785-798. doi: 10.1016/S1470-2045(18)30242-0. Epub 2018 May 9.
引用本文的文献
1
Patient Acceptability of the First Integrative Pediatric Oncology Unit in Spain-The Pediatric Cancer Center Barcelona Experience: A Retrospective Study.
Cancers (Basel). 2025 Jan 11;17(2):222. doi: 10.3390/cancers17020222.
2
Multimodal Analgesia in Pediatric Cancer Pain Management: A Retrospective Single-Center Study.
Cureus. 2023 Sep 14;15(9):e45223. doi: 10.7759/cureus.45223. eCollection 2023 Sep.
3
Biochemistry-Not Oncogenes-May Demystify and Defeat Cancer.
Oncol Ther. 2023 Jun;11(2):153-169. doi: 10.1007/s40487-023-00221-y. Epub 2023 Feb 13.
4
Parental Views of Social Worker and Chaplain Involvement in Care and Decision Making for Critically Ill Children with Cancer.
Children (Basel). 2022 Aug 26;9(9):1287. doi: 10.3390/children9091287.
5
Mortality of Hemato-Oncologic Patients Admitted to a Pediatric Intensive Care Unit: A Single-Center Experience.
Front Pediatr. 2022 Jul 12;10:795158. doi: 10.3389/fped.2022.795158. eCollection 2022.
6
Suspected Adverse Drug Reactions in Pediatric Cancer Patients in China: An Analysis of Henan Province Spontaneous Reporting System Database.
Front Oncol. 2021 Dec 20;11:807171. doi: 10.3389/fonc.2021.807171. eCollection 2021.
7
Applications of Artificial Intelligence in Pediatric Oncology: A Systematic Review.
JCO Clin Cancer Inform. 2021 Dec;5:1208-1219. doi: 10.1200/CCI.21.00102.
8
Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System.
Front Pharmacol. 2020 May 7;11:621. doi: 10.3389/fphar.2020.00621. eCollection 2020.
9
Identification of lncRNAs Associated With Neuroblastoma in Cross-Sectional Databases: Potential Biomarkers.
Front Mol Neurosci. 2019 Dec 12;12:293. doi: 10.3389/fnmol.2019.00293. eCollection 2019.
10
A Scoping Review of Physical Therapy Interventions for Childhood Cancers.
Physiother Can. 2019 Summer;71(3):287-296. doi: 10.3138/ptc.2018-13.pp.
本文引用的文献
1
microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies.
Clin Cancer Res. 2009 Sep 1;15(17):5560-8. doi: 10.1158/1078-0432.CCR-08-3287. Epub 2009 Aug 25.
2
Copy number variation at 1q21.1 associated with neuroblastoma.
Nature. 2009 Jun 18;459(7249):987-91. doi: 10.1038/nature08035.
3
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.
Nat Genet. 2009 Jun;41(6):718-23. doi: 10.1038/ng.374. Epub 2009 May 3.
4
Identification of ALK as a major familial neuroblastoma predisposition gene.
Nature. 2008 Oct 16;455(7215):930-5. doi: 10.1038/nature07261. Epub 2008 Aug 24.
5
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.
J Natl Cancer Inst. 2008 Jul 2;100(13):940-9. doi: 10.1093/jnci/djn176. Epub 2008 Jun 24.
6
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.
N Engl J Med. 2008 Jun 12;358(24):2585-93. doi: 10.1056/NEJMoa0708698. Epub 2008 May 7.
7
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Genes Chromosomes Cancer. 2006 Jun;45(6):583-91. doi: 10.1002/gcc.20322.
8
Chromosome 1p and 11q deletions and outcome in neuroblastoma.
N Engl J Med. 2005 Nov 24;353(21):2243-53. doi: 10.1056/NEJMoa052399.
9
Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
J Clin Oncol. 2005 Oct 10;23(29):7312-21. doi: 10.1200/JCO.2005.01.2799. Epub 2005 Aug 29.
10
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.
Cell. 2005 Jan 14;120(1):15-20. doi: 10.1016/j.cell.2004.12.035.
Zotero 插件